Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

BACKGROUND: Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1 (PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a patient’s own immune system to increase anti-tumor activity. While immunocheckpoint blockad...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, Gregory S., Palmer, Joshua D., Tuluc, Madalina, Lin, Jianqing, Dicker, Adam P., Bar-Ad, Voichita, Harshyne, Larry A, Louie, Jennifer, Shaw, Colette M., Hooper, D. Craig, Lu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034602/
https://www.ncbi.nlm.nih.gov/pubmed/27663515
http://dx.doi.org/10.1186/s13045-016-0328-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034602/
https://www.ncbi.nlm.nih.gov/pubmed/27663515
http://dx.doi.org/10.1186/s13045-016-0328-4

Ejemplares similares